Stiolto generic?

Stiolto is the brand name for a fixed‑dose combination tablet containing two angiotensin‑II receptor blockers (ARBs):

Together they provide a single‑pill “dual ARB” therapy that can help patients with hypertension who need a stronger blood‑pressure reduction than one ARB alone.

Generic availability

• United States
  The FDA has approved generic versions of both olmesartan and azilsartan separately.
  In 2023 the FDA approved a generic dual ARB combination that mirrors Stiolto’s 20 mg/10 mg formulation. The generic product carries no brand name; pharmacies typically list it simply as “Olmesartan + Azilsartan medoxomil, 20 mg / 10 mg, tablets”.

• Europe
  Several EU countries have generic dual‑ARB tablets available under various manufacturer names, e.g., “Olmesartan‑Azilsartan” (20 mg / 10 mg).
  The European Medicines Agency (EMA) cleared the combination in 2020, and generic manufacturers now supply it.

• Canada
  The Health Canada Drug Product Database lists a generic dual‑ARB combination approved in 2023 under the same 20 mg/10 mg dose.

• Australia & New Zealand
  Generics for the dual‑ARB combo were approved in 2023, and pharmacies can dispense the 20 mg/10 mg tablets under the generic designation.

Why use a generic?

How it works

Both olmesartan and azilsartan block the angiotensin‑II type 1 receptors, preventing vasoconstriction and aldosterone release. The combination can achieve a greater antihypertensive effect than either drug alone, particularly in patients who are “uncontrolled” on a single ARB.

Common side‑effects (generic or brand)

• Dizziness or light‑headedness (especially after the first dose)
• Headache
• Fatigue
• Upper respiratory infections
• Hyperkalemia (high potassium) – monitor electrolytes if you have kidney disease or take potassium‑sparing diuretics
• Low blood pressure (hypotension)

If you develop severe dizziness, fainting, swelling of the face/neck/lips, or breathing difficulty, seek medical help immediately.

Precautions & Contraindications

• Pregnancy – ARBs are contraindicated; they can cause fetal kidney damage.
• Kidney impairment – dose adjustments may be needed; monitor renal function.
• Hyponatremia – can worsen sodium imbalance.
• Interactions – avoid potassium‑sparing diuretics, ACE inhibitors, or other ARBs to reduce the risk of hyperkalemia and renal dysfunction.

What to ask your pharmacist or prescriber

1. Cost & insurance coverage – will the generic be covered under your plan?
2. Monitoring plan – how often will blood pressure, electrolytes, and kidney function be checked?
3. Switching – if you’re moving from Stiolto to a generic, ensure you understand the dosing schedule (usually identical, 20 mg/10 mg once daily).

Bottom line

• Stiolto is a brand‑name dual ARB therapy.
• Generics are available in most major markets and offer the same efficacy and safety profile at a lower cost.
• If you’re already taking Stiolto and want a generic, talk with your prescriber; they can prescribe the 20 mg/10 mg olmesartan‑azilsartan tablet.

Feel free to ask if you need help interpreting lab results, managing side‑effects, or coordinating your medication list!